Morgan Hill, CA, United States of America

Stefanie Ann Ward Mortimer

This inventor holds 60 USPTO granted patents and 25 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Nucleic Acid Analysis. Top assignees: Guardant Health, Inc., Other. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefanie Ann Ward Mortimer. Retrieved from https://idiyas.com/inventor/stefanie-ann-ward-mortimer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 60 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 2.8

ph-index = 13

Forward Citations = 445(Granted Patents)

Forward Citations (Not Self Cited) = 180(Dec 10, 2025)


Company Filing History:


Years Active: 2017-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cancer Detection
Nucleic Acid Analysis
Genetic Variants
Cell-Free DNA
Rare Mutations
Copy Number Variation
Methylation Partitioning
Multi-Resolution Analysis
Sequence Reads
Molecular Residual Disease
Analyzing Nucleic Acids
Genetic Testing
60 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Stefanie Ann Ward Mortimer in Cancer Detection**

Introduction

Stefanie Ann Ward Mortimer, based in Morgan Hill, CA, is a prominent inventor in the field of cancer detection with an impressive portfolio of 46 patents. Her groundbreaking work focuses on developing methods and technologies that significantly enhance the early diagnosis of cancer, making it one of the critical advancements in medical science.

Latest Patents

Among her latest inventions, Mortimer has disclosed several methods for early cancer detection. These methods involve preparing cell-free nucleic acid molecules from asubject for sequencing and identifying cancer indicators. Additionally, she has developed systems and methods to detect rare mutations and copy number variations. This innovation entails extracting and isolating cell-free polynucleotide sequences from bodily fluids, followed by sequencing and applying bioinformatics tools to accurately identify genetic anomalies. Such advancements are invaluable in improving cancer profiling and diagnosis.

Career Highlights

Throughout her career, Mortimer has significantly contributed to the field, demonstrating exceptional expertise in molecular biology and oncology diagnostics. Her affiliation with Guardant Health, Inc. underscores the impact of her work in advancing cancer detection methodologies.

Collaborations

Mortimer has collaborated with notable professionals in the field, including Amirali Talasaz and Helmy A Eltoukhy. Their combined expertise in biotechnology and molecular diagnostics has led to innovative breakthroughs in understanding and detecting cancer at its early stages.

Conclusion

Stefanie Ann Ward Mortimer's contributions to cancer detection through her numerous patents highlight her role as a leading inventor in the medical field. Her innovative approaches not only pave the way for early diagnosis but also enhance the understanding of genetic mutations related to cancer, ultimately improving patient outcomes. Mortimer’s work exemplifies the profound influence of innovation in healthcare and the continual fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…